Search

VENTANA ALK (D5F3) CDx Assay (US FDA Approved)

Identifying ALK+ NSCLC patients for targeted treatment

VENTANA ALK (D5F3) CDx Assay (PMA)
Identifying ALK+ NSCLC patients for targeted treatment

The VENTANA ALK (D5F3) CDx Assay empowers your lab to provide timely results with a four-and-one-half hour run time using fully automated, ready-to-use reagents.

Image of HCP slide viewing ALK IHC assay for lung cancer patient

Related portfolios

Related topic

Related links

Compare VENTANA ALK (D5F3) CDx Assay performance: UK NEQAS

Compare VENTANA ALK (D5F3) CDx Assay performance: NordiQC

XALKORI.com

ZYKADIA.com

ALECENSA.com

LORBRENA.com

Roche eLabDoc: product catalogs and documentation

Contact Us
About the VENTANA ALK (D5F3) CDx Assay
  • VENTANA ALK (D5F3) CDx Assay stained with OptiView DAB Detection and Amplification detects the ALK protein that is the target of therapy
  • Clinical guidelines recommend rapid turnaround for earlier targeted therapies
  • ALK has comparable sensitivity and specificity relative to FISH
  • Make more immediate treatment decisions for advanced NSCLC patients by using the VENTANA ALK (D5F3) CDx Assay
Roche ALK lung cancer patient and stain image

Available therapies

Roche ALK lung cancer patient and HCP

XALKORI® (crizotinib), ZYKADIA® (ceritinib), ALECENSA® (alectinib) and LORBRENA® (lorlatinib) are clinically effective and FDA approved for the treatment of patients with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved testing method for ALK.1,3,7

 

  • XALKORI (crizotinib) is indicated for the treatment of patients with ALK positive metastatic NSCLC and other kinases¹
  • ZYKADIA (ceritinib) is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib³
  • ALECENSA (alectinib) is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib7
  • LORBRENA (lorlatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease
View Full Table
close
  VENTANA ALK (D5F3) CDx Assay with OptiView DAB Detection and Amplification
 ALK FISH

Scoring process
  • Binary (+/-) scoring
  • Any strong positive staining in any number of cells is positive for ALK
  • Requires a dual color scoring algorithm
  • Requires 50 enumerable cells and specific cutoff ratios to be calculated
Turnaround times
  • 4.5 hours, fully automated
  • Routine IHC testing
  • 12+ hours, semi-automated
  • Typically batch or send-out testing
Brightfield vs. fluorescent staining
  • Standard brightfield microscope
  • Fully archivable results
  • Full visibility of tumor morphology
  • Requires a fluorescent microscope
  • Staining and signal fade over time
  • Loss of tissue morphology
VENTANA ALK (D5F3) CDx Assay and detection with amplification vs. FISH

In one study, van der Wekken et al. “…found that dichotomous ALK-IHC is superior to ALK-FISH on small biopsies and fine-needle aspirations (FNA) to predict tumor response and survival to crizotinib for patients with advanced NSCLC.”7

Intended use

VENTANA ALK (D5F3) CDx Assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORI® (crizotinib), ZYKADIA® (ceritinib), ALECENSA® (alectinib) or LORBRENA® (lorlatinib).

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This product is intended for in vitro diagnostic (IVD) use.

Screenshot of doc library

Find out more about the VENTANA ALK (D5F3) CDx Assay

Search our product catalogs and documentation library in eLabDoc.

You might be interested in

...
    ...

    References

    1. XALKORI® (crizotinib) [package insert], New York, NY: Pfizer; 2012.
    2. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F. (2012). GLOBOCAN v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr (accessed March 2016).
    3. ZYKADIA (ceritinib) [package insert], Whippany, NJ: Novartis Pharmaceuticals Corporation 2016.
    4. ALECENSA (alectinib) [package insert], San Francisco, CA: Genentech; 2017.
    5. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France http://globocan.iarc.fr/ Default.aspx. Accessed August 1, 2014.
    6. Lung Cancer Survival Rates and Prognosis. National Cancer Institute at the National Institutes of Health. Bethesda, MD. http://www.cancer.gov
    7. van der Wekken et al Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer, Clinical Cancer Research, 2017. Available at http://clincancerres.aacrjournals.org
    8. Zhou J, Zhao J, Sun K, Wang B, Wang L, et al. Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening. PLoS ONE (2014) 9(3): e92828. doi:10.1371/journal.pone.0092828.
    9. Ling Shan, Fang Lian, Lei Guo, Xin Yang, Jianming Ying and Dongmei Lin. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. Diagnostic Pathology 2014, 9:3. doi:10.1186/1746-1596-9-3.
    10.  Ying, J.; Guo, L.; Qiu, T.; Shan, L.; Ling, Y.; Liu, X.; Lu, N. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Annals of Oncology. 24(10):2589-2593, October 2 Modern Pathology (2013) 26, 1545–1553; doi:10.1038/modpathol.2013.87; published online 7 June 2013.
    11. Mok T, Peters S, Camidge DR. Patients with ALK IHC-positive/fish-negative NSCLC benefit from ALK TKI treatment: response data from the global ALEX trial. Presented at: the IASLC 18th World Conference on Lung Cancer; October 15-18; Yokohama, Japan. Poster MA 07.01
    12. LORBRENA (lorlatinb)[package insert], New York, New York: Pfizer; 2020

    Related products

    product box for cobas EZH2
    cobas® EZH2 Mutation Test
    VENTANA HER2 Dual ISH DNA Probe Cocktail Assay CDx icon
    VENTANA HER2 Dual ISH DNA Probe Cocktail assay (CE IVD)
    HER2 DUAL ISH thumbnail image
    VENTANA HER2 Dual ISH DNA Probe Cocktail assay (US FDA Approved)
    VENTANA MMR RxDx panel icon
    VENTANA MMR RxDx Panel (US FDA Approved)
    VENTANA PD-L1 SP142 Assay
    VENTANA PD-L1 (SP142) Assay (US FDA Approved)
    VENTANA FOLR1 (FOLR-2.1) RxDx Assay (US FDA Approved)
    VENTANA FOLR1 (FOLR1-2.1) RxDx Assay
    VENTANA anti-ALK (D5F3), lung carcinoma
    VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (CE IVD)
    VENTANA MMR RxDx panel icon
    VENTANA MMR RxDx Panel (CE IVD)
    cobas® 4800 BRAD V600 Mutation Test
    cobas® 4800 BRAF V600 Mutation Test
    Roche Pathway HER2 4B5 assay slide and therapy image
    PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody
    Roche VENTANA HER2 4B5 breast cancer IHC stain
    VENTANA anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (CE IVD)
    VENTANA PD-L1 (SP263) Assay, non-small cell lung cancer (NSCLC), urothelial carcinoma, bladder cancer
    VENTANA PD-L1 (SP263) Assay (CE IVD)